InteKrin Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $5M

InteKrin General Information

Description

Developer of treatment of immune disorders designed to offer novel treatments that provide patients with better treatment alternatives. The company's immune disorder treatment includes INT131, a non-TZD peroxisome proliferator-activated receptor gamma modulator and focused on treating Relapsing Remitting Multiple Sclerosis, enabling physicians to meet the dual needs of neuroprotection and stopping the otherwise relentless progression of this devastating disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 201 Redwood Shores Parkway
  • Suite 200
  • Redwood City, CA 94065
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 201 Redwood Shores Parkway
  • Suite 200
  • Redwood City, CA 94065
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InteKrin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 12-Feb-2014 $5M Completed Clinical Trials - General
6. Later Stage VC 10-Jun-2010 Completed Startup
5. Later Stage VC 02-Apr-2009 Completed Startup
4. Later Stage VC (Series C) 10-Oct-2008 Completed Startup
3. Early Stage VC 19-Mar-2008 Completed Startup
2. Early Stage VC 11-Jan-2007 $6.98M $6.98M Completed Startup
1. Early Stage VC (Series A) Completed Startup
To view InteKrin’s complete valuation and funding history, request access »

InteKrin Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of treatment of immune disorders designed to offer novel treatments that provide patients with better treatmen
Drug Discovery
Redwood City, CA

Durham, NC
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InteKrin Competitors (48)

One of InteKrin’s 48 competitors is Argos Therapeutics, a Venture Capital-Backed company based in Durham, NC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Argos Therapeutics Venture Capital-Backed Durham, NC
Xalud Therapeutics Venture Capital-Backed New York, NY
Centrexion Therapeutics Venture Capital-Backed Boston, MA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Rein Therapeutics Formerly VC-backed Austin, TX
You’re viewing 5 of 48 competitors. Get the full list »

InteKrin Patents

InteKrin Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017326261-A1 Treatment of multiple sclerosis with chs-131 Inactive 13-Sep-2016
CA-3036694-A1 Treatment of multiple sclerosis with chs-131 Inactive 13-Sep-2016
EP-3512512-A1 Treatment of multiple sclerosis with chs-131 Inactive 13-Sep-2016
EP-3512512-A4 Treatment of multiple sclerosis with chs-131 Inactive 13-Sep-2016
US-20190224186-A1 Treatment of multiple sclerosis with chs-131 Inactive 13-Sep-2016 A61K31/47
To view InteKrin’s complete patent history, request access »

InteKrin Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amgen Corporation Minority
Asset Management Ventures Venture Capital Minority
Hunt BioVentures Venture Capital Minority
Lanfear Capital Venture Capital Minority
OrbiMed Growth/Expansion Minority
You’re viewing 5 of 10 investors. Get the full list »

InteKrin FAQs

  • When was InteKrin founded?

    InteKrin was founded in 2005.

  • Where is InteKrin headquartered?

    InteKrin is headquartered in Redwood City, CA.

  • What industry is InteKrin in?

    InteKrin’s primary industry is Drug Discovery.

  • Is InteKrin a private or public company?

    InteKrin is a Private company.

  • What is the current valuation of InteKrin?

    The current valuation of InteKrin is .

  • What is InteKrin’s current revenue?

    The current revenue for InteKrin is .

  • How much funding has InteKrin raised over time?

    InteKrin has raised $73.9M.

  • Who are InteKrin’s investors?

    Amgen, Asset Management Ventures, Hunt BioVentures, Lanfear Capital, and OrbiMed are 5 of 10 investors who have invested in InteKrin.

  • Who are InteKrin’s competitors?

    Argos Therapeutics, Xalud Therapeutics, Centrexion Therapeutics, Inovio Pharmaceuticals, and Rein Therapeutics are some of the 48 competitors of InteKrin.

  • When was InteKrin acquired?

    InteKrin was acquired on 12-Feb-2014.

  • Who acquired InteKrin?

    InteKrin was acquired by Coherus Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process